Tilray Medical Brings Its Cannabis Flower Direct to UK Patients

Tilray Medical has begun selling its own branded cannabis flower directly to UK patients through the Lyphe Clinic and Lyphe Dispensary it acquired in April 2026, the company announced on August 17, 2026, turning an April acquisition into a working supply chain that runs from European cultivation to a British patient’s door.

The launch makes Tilray Medical-branded cannabis flower available through Lyphe Clinic and Lyphe Dispensary, creating what the company describes as its first direct-to-patient channel in the UK. Rather than supplying British pharmacies as an outside wholesaler, Tilray can now cultivate and manufacture in Europe, prescribe through its own clinic, dispense through its own pharmacy, and manage patient support inside one connected structure.

“This launch is a defining step in Tilray Medical’s UK strategy and a powerful example of how we are building a more connected, patient-centered medical cannabis platform,” Rajnish Ohri, President of International at Tilray Brands, said in the announcement. “By bringing Tilray Medical-branded cannabis medicines to patients through Lyphe Clinic and Lyphe Dispensary, we are combining high-quality European cultivation and pharmaceutical manufacturing with trusted clinical, prescribing, dispensing and patient care services.”

The company framed the launch as an expansion of responsible access in a regulated market, with the range available through Lyphe expected to grow over the coming months. The products will be cultivated and produced through Tilray’s international production network, including its EU-GMP-certified facility in Portugal.

How the Lyphe Deal Built This Channel

The August launch is the operational payoff of an acquisition Tilray announced on April 15, 2026, when it acquired the Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform. At the time, Lyphe Dispensary had dispensed approximately 150,000 units to date, and Lyphe Clinic had treated more than 16,000 patients.

That acquisition gave Tilray what it called its first fully vertically integrated, patient-centric medical platform, combining pharmaceutical-grade cultivation and production with clinical care, dispensing services, and pharmaceutical distribution. Tilray has been extending its reach through acquisitions this year; in July 2026 it acquired the HelloMD telehealth platform in a court-supervised sale, adding another patient-facing digital asset.

The company’s European buildout has been years in the making. Tilray grew from one of Canada’s first licensed medical cannabis producers into the operator of what it describes as the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. It has also been deepening its European presence publicly, expanding its push at Cannabis Europa in London earlier in 2026.

The UK Rules That Shape This Rollout

The launch operates inside a specific legal structure. Medical cannabis has been legal in the UK since November 1, 2018, but only when prescribed by a specialist doctor who has weighed the current evidence and guidelines against a patient’s particular diagnosis and conditions, according to Lyphe Clinic’s published patient guidance. It is not available over the counter, and general practitioners do not initiate it.

Eligibility narrows the pool further. Lyphe’s guidance states that patients generally must have tried other pharmaceutical or therapeutic treatments that have not worked, and must not have been diagnosed with psychosis or schizophrenia. In practice, this is why a vertically integrated clinic matters: the prescriber sits inside the system, so the company controls the pathway from eligibility check to prescription to dispensing.

Lyphe’s model is built around that pathway, with eligibility checks, video appointments with specialist clinicians, and repeat prescriptions dispensed through its own dispensary. Tilray’s flower now flows through that existing infrastructure rather than requiring a new one to be built.

Tilray’s Numbers Behind the UK Push

The acquisition and launch sit on a measurable patient and production base:

• 16,000+ patients treated by Lyphe Clinic as of the April 15, 2026 acquisition
• ~150,000 units dispensed by Lyphe Dispensary as of the same date
• 20 countries across five continents where Tilray Medical supplies patients, physicians, hospitals, pharmacies, researchers and governments
• 2 European GMP-certified production facilities, in Portugal and Germany
• 40+ brands across Tilray Brands’ wider portfolio, spanning cannabis, hemp-based foods and craft beverages

The Portugal facility is the production anchor for the UK launch, supplying EU-GMP-certified flower into the British market. The products are cultivated and produced through Tilray’s international production network, including its EU-GMP-certified facility in Portugal, the company said.

What Comes Next for the UK Channel

The range of Tilray Medical products available through Lyphe Clinic and Lyphe Dispensary is expected to expand over the coming months, the company said, extending beyond the initial cannabis flower offering. The company has not put a specific product count or date on that expansion.

On the financial side, Tilray said in April that it expects the Lyphe business to be accretive in 2027, giving the UK platform a defined target against which the direct-to-patient model will be measured. Tilray also said it would use its CC Pharma distribution arm to supply medications through the Lyphe platform more efficiently, extending the channel beyond cannabis into traditional prescription medicines.

For now, the launch converts a four-month-old acquisition into a functioning pipeline: European-grown, EU-GMP-certified flower, prescribed by a Tilray-owned clinic and dispensed by a Tilray-owned pharmacy, reaching patients across the UK and the Channel Islands under the specialist-prescription rules that have governed the market since 2018.